Vitamin D3
Vitamin D is a fat-soluble vitamin the body uses for normal calcium and phosphorus absorption, bone and muscle maintenance, and immune function. UK NHS guidance recommends 10 µg/day (400 IU) for everyone aged four and over from October to March, when UK latitude limits the skin's ability to synthesise vitamin D from sunlight.
Camden Medicals editorial · Last reviewed 25 April 2026 · Next review April 2027
- Cross-checked against
- NHS
- NICE
- BNF
- EFSA
- FSA
Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.
- Class
- Vitamin
- NHS daily RNI
- 10 µg
- Typical supplemental
- 10–25 µg/day (400–1,000 IU/day) for routine supplementation.
- Top use evidence
- Strong
On this page
What it is
Vitamin D is a fat-soluble secosteroid. Two forms reach the body: cholecalciferol (D3) made in skin from 7-dehydrocholesterol on UVB exposure or sourced from animal foods (oily fish, egg yolk, liver), and ergocalciferol (D2) sourced from yeast and some mushrooms.
Both forms are converted in the liver to 25-hydroxyvitamin D — the storage form measured by blood tests — and then in the kidney to the active 1,25-dihydroxyvitamin D, which acts as a hormone on receptors throughout the body.
UK food sources are limited (oily fish, egg yolk, fortified cereals and spreads). For most UK adults, dietary intake alone is below adequacy from October to March, which is why the NHS makes a routine supplementation recommendation for that window.
At a glance
- NHS recommends 10 µg/day (400 IU) October–March for everyone aged 4+, year-round for adults with darker skin or limited sun exposure.
- NHS recommends 10 µg/day in pregnancy and breastfeeding.
- D3 (cholecalciferol) gives a slightly higher rise in serum 25(OH)D than D2 (ergocalciferol).
- Megadosing past adequacy has not delivered the headline benefits in large UK trials.
What people use it for
Adults Oct–Mar in the UK
NHS official recommendation: 10 µg/day during low-UVB months. UK latitude limits skin synthesis from October to March. [1,2]
Some evidenceStrongAdults with darker skin pigmentation, year-round
Melanin reduces UVB-driven vitamin D synthesis. NHS recommends year-round supplementation at 10 µg/day for these adults. [1]
Some evidenceStrongPregnancy and breastfeeding
NHS recommends 10 µg/day in pregnancy and breastfeeding, with year-round supplementation specifically advised for women in at-risk groups (darker skin, limited sun exposure, covered clothing). Free supplements are available via the UK Healthy Start scheme for eligible women. [1,5]
Some evidenceStrongChildren aged 1–4 years
NHS recommends a daily 10 µg supplement for all children aged 1 to 4. Babies under 1 having less than 500 ml a day of infant formula may also need a supplement. [1]
Some evidenceStrongAdults over 65 / housebound / institutionalised adults
NICE PH56 (Vitamin D: supplement use in specific population groups) names this population as a priority group; UK SACN reaches the same conclusion. The GB-authorised falls-risk-reduction claim applies to supplements delivering ≥15 µg/day to men and women aged 60+. [3,2,6]
Some evidenceStrongAdults who eat oily fish multiple times a week and get summer sun
Dietary intake plus summer skin synthesis is likely adequate during Apr–Sep. Routine supplementation may not be needed outside the NHS Oct–Mar window. [1]
Some evidenceModerate
How it works
The active hormone 1,25-dihydroxyvitamin D binds to the vitamin D receptor in target tissues, regulating genes that control calcium and phosphate absorption in the gut, bone remodelling, and immune-cell activity. Adequacy is needed for these systems to function as expected.
Common myths
Myth"Higher-dose vitamin D produces bigger health benefits"
RealityLarge UK and international RCTs at supra-NHS doses have generally been null for headline outcomes in non-deficient adults. The strong NHS recommendation is for adequacy (10 µg/day), not megadosing. [2]
Myth"D2 and D3 are interchangeable"
RealityD3 (cholecalciferol) tends to give a slightly higher and more sustained rise in serum 25(OH)D than D2 (ergocalciferol). D2 still works and is suitable for vegan formulations; the difference is modest, not dramatic. [7]
Myth"You need a blood test before taking 10 µg/day"
Reality10 µg/day is the NHS adequacy dose and is generally considered safe for adults without a blood test. Testing is more relevant for higher doses, suspected deficiency, or specific conditions (osteoporosis, malabsorption). [1]
Common online questions
Synthesised from the questions UK shoppers most often ask online about Vitamin D3. Each answer is editorial and links to its evidence in the Sources list below.
Should I keep taking vitamin D in summer too?
The NHS recommendation is a daily 10 µg supplement during autumn and winter (October to March) for everyone in the UK, because UVB at this latitude is too weak to drive skin synthesis. From April to September most people make enough from short, regular sun exposure to skin (without burning), but the NHS specifically recommends year-round supplementation for people with darker skin, those who cover most of their skin when outside, and anyone housebound or institutionalised. If your sun exposure in summer is limited, year-round supplementation is sensible. [1]
D2 vs D3 — does it matter which I buy?
Both work. A 2012 meta-analysis (Tripkovic et al., AJCN) found that D3 (cholecalciferol) gives a slightly higher and more sustained rise in serum 25(OH)D than D2 (ergocalciferol) per equivalent dose. The difference is modest at the doses used in UK food supplements. D2 is suitable for vegan formulations; D3 is the more common over-the-counter form. [7]
Is 4,000 IU (100 µg) per day too much?
100 µg / 4,000 IU per day is the UK adult upper limit for total intake from food and supplements combined. That is forty times the NHS recommended supplemental amount of 10 µg / 400 IU per day. Doses up to the upper limit are not recommended as routine — they should be on clinical advice. Sustained intakes above the upper limit raise the risk of hypercalcaemia (high blood calcium). The NHS publishes lower upper limits for children (50 µg for ages 1–10; 25 µg for under 1). [1]
Will vitamin D help with low mood in winter (SAD)?
Vitamin D adequacy contributes to normal nervous-system function — that is the GB-authorised claim. Whether supplementation treats seasonal affective disorder is a separate question; large randomised trials in non-deficient adults have not consistently shown a mood benefit. If low winter mood is affecting your day-to-day, talk to your GP about evidence-based options (light therapy, talking therapy, medication). Vitamin D adequacy is sensible alongside, not instead of, those. [6,8]
Should I take vitamin D with K2?
Co-supplementing vitamin D with vitamin K2 is a popular framing in the supplement market, on the theory that K2 directs calcium toward bone rather than soft tissue. The clinical-outcome evidence in healthy adults is limited; the GB Nutrition and Health Claims Register does not authorise a "K2 directs calcium to bone" claim. If you want vitamin K, dietary sources (green leafy vegetables for K1; some fermented foods and animal foods for K2) are usually adequate. If you take warfarin, do not add a vitamin K supplement without your GP''s advice — it can affect anticoagulation.
Why does the NHS recommend exactly 10 µg?
10 µg (400 IU) per day is the SACN 2016 recommended Reference Nutrient Intake for adults and children over 4. SACN derived the figure from the daily intake required to keep serum 25(OH)D above the deficiency threshold (25 nmol/L) in 97.5% of UK adults during winter — when sun exposure is the lowest the figure has to bridge the gap entirely. [2]
⚖️ The official position
What may lawfully be claimed about Vitamin D3 in Great Britain. This is a regulatory position, not an evidence grade.
A health claim is authorised in Great Britain.
“Vitamin D contributes to the normal function of the immune system”
“Vitamin D contributes to the maintenance of normal bones”
“Vitamin D contributes to the maintenance of normal teeth”
“Vitamin D contributes to the maintenance of normal muscle function”
“Vitamin D contributes to normal absorption/utilisation of calcium and phosphorus”
“Vitamin D contributes to normal blood calcium levels”
“Vitamin D has a role in the process of cell division”
This claim is authorised for use in Great Britain under the GB Nutrition and Health Claims regulation. A product may carry it when it provides at least 15% of the UK NRV per recommended daily portion.
Authorised UK health claims
Verbatim from the GB Nutrition and Health Claims Register (Reg 432/2012 as assimilated in GB). A product can carry these claims when it provides at least 15% of the UK NRV per recommended daily portion.
7 authorised claims — show / hide
- "Vitamin D contributes to the normal function of the immune system"
- "Vitamin D contributes to the maintenance of normal bones"
- "Vitamin D contributes to the maintenance of normal teeth"
- "Vitamin D contributes to the maintenance of normal muscle function"
- "Vitamin D contributes to normal absorption/utilisation of calcium and phosphorus"
- "Vitamin D contributes to normal blood calcium levels"
- "Vitamin D has a role in the process of cell division"
Camden guides citing Vitamin D3
Editorial pieces from the Camden blog that reference Vitamin D3. Each guide cites the evidence it draws on.
🔬 Camden’s evidence review
The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.
Bone health and falls (older adults)
StrongEvidencestrongRoutine adequacy of vitamin D, alongside calcium where dietary intake is low, is supported by NICE PH56 and SACN for bone maintenance and falls prevention in older adults. The GB-authorised falls-risk- reduction claim applies to supplements delivering ≥15 µg/day to men and women aged 60+. [3,2,6]
Cancer prevention (general adult population)
InsufficientEvidenceinsufficientLarge recent randomised trials (e.g. VITAL, Manson NEJM 2019) have not shown reductions in total cancer incidence with vitamin D supplementation in non-deficient adults at the doses studied (cancer HR 0.96, P=0.47). [8]
Cardiovascular events (general adult population)
InsufficientEvidenceinsufficientLarge randomised trials (VITAL, Manson NEJM 2019) have not shown reductions in major cardiovascular events with vitamin D supplementation in non-deficient adults (CV HR 0.97, P=0.69). [8]
Acute respiratory tract infection prevention
MixedEvidencemixedThe Martineau BMJ 2017 IPD meta-analysis showed a small protective effect, mostly in deficient subjects and with daily (not bolus) dosing. Subsequent large trials weakened the signal in non-deficient adults. [9]
Safety
Vitamin D3 has an excellent safety profile at NHS-recommended doses (10 µg / 400 IU per day). The NHS recommends a daily 10 µg supplement during autumn and winter for all UK adults, and year-round for at-risk groups.
Talk to your pharmacist or GP first if you:
- You have a history of high blood calcium (hypercalcaemia) or kidney stones.
- You have sarcoidosis or another granulomatous disease (vitamin D activation can be dysregulated).
- You take a thiazide diuretic (vitamin D + thiazide can raise blood calcium).
- You take orlistat, cholestyramine, or another bile-acid sequestrant — these reduce vitamin D absorption (separate dosing).
- You take long-term corticosteroids or certain anticonvulsants (these can increase your vitamin D requirement).
- You are pregnant, breastfeeding, or thinking of becoming pregnant.
Common side effects: Uncommon at standard doses (≤25 µg / 1,000 IU per day). At sustained doses well above the 100 µg / 4,000 IU adult upper limit, the main risk is hypercalcaemia (high blood calcium).
Pregnancy and breastfeeding
The NHS recommends 10 µg (400 IU) of vitamin D per day in pregnancy, specifically advising supplementation during autumn and winter, with year-round supplementation for women in at-risk groups (darker skin, limited sun exposure, covered clothing). Free supplements are available via the UK Healthy Start scheme for eligible women. Note: high doses of vitamin A from liver or retinol-containing supplements should be avoided in pregnancy — that is a vitamin A caution, separate from vitamin D.
10 µg/day during breastfeeding, particularly in autumn and winter; year-round for at-risk groups.
Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.
More clinical detail (for clinicians and informed readers)
Contraindications
- Hypercalcaemia or active sarcoidosis — discuss with your GP before supplementing.
- Granulomatous diseases — vitamin D activation can be dysregulated; specialist advice is needed.
Drug interactions
- Thiazide diuretics — may raise serum calcium; monitor.
- Some anticonvulsants and corticosteroids — may increase vitamin D requirement; clinical advice indicated.
- Orlistat — reduces absorption of fat-soluble vitamins including vitamin D; separate dosing or monitor (colecalciferol SmPC 4.5).
- Cholestyramine / colestyramine and other bile-acid sequestrants — reduce vitamin D absorption; separate dosing (colecalciferol SmPC 4.5).
This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.
Common side effects
- At standard doses (≤25 µg/day), uncommon. Mild digestive complaints occasionally reported.
Rare side effects
- Hypercalcaemia — only at sustained doses well above the UL or in conditions affecting calcium handling.
How to take it
- UK Reference Nutrient Intake
- 10 µg/day
- Typical supplemental range
- 10–25 µg/day (400–1,000 IU/day) for routine supplementation.
- Timing
- With a meal containing some fat improves absorption (vitamin D is fat-soluble).
How to spot quality
Look for
- Cholecalciferol (D3) declared explicitly — for vegan formulations, ergocalciferol (D2) or a vegan-source D3 is also acceptable.
- Both µg and IU printed on the label (10 µg = 400 IU).
- Oil-based softgel or oral spray for better absorption versus a dry tablet (modest difference, but real).
- GMP-certified manufacture; ideally third-party potency testing.
Red flags
- Label says "vitamin D" without specifying D2 or D3.
- Megadose marketing without specific clinical context (e.g. "10,000 IU daily" framed as routine).
- Combined "D3 + K2" sold with cardiovascular claims that are not authorised in GB.
Where Camden lands · meets the bar
Vitamin D3 in Camden's catalogue currently appears as a co-ingredient in NB-537 (Shilajit Complex) at 5 µg (200 IU) per 2-capsule serving — 100% of the UK NRV (5 µg) but half the NHS recommended-intake of 10 µg/day. A standalone Vitamin D3 product is not yet in the catalogue; for routine Oct–Mar adequacy, a separate 10 µg vitamin D3 supplement is the simplest path. We are evaluating a standalone NB- vitamin D3 SKU.
Commonly combined with
Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.
Vitamin K2 (Menaquinone)
Moderate evidenceK2 directs the calcium that D3 helps you absorb into bones — and away from arteries.
Vitamin D3 (cholecalciferol) is hydroxylated in the liver to 25-hydroxy-D and then in the kidney to the active 1,25-dihydroxy form, which upregulates intestinal calcium absorption and bone remodelling. Vitamin K2 (menaquinone-7) is the cofactor for two gamma-glutamyl carboxylase reactions that activate osteocalcin in bone (binds calcium into the bone matrix) and matrix-Gla-protein in vascular tissue (inhibits soft-tissue calcification). The combination is theorised to maximise the bone-building effect of D3 while reducing the risk of arterial calcification associated with high-dose D3 in K-insufficient adults. EFSA has authorised individual claims for both vitamins; no combined-stack claim exists, and long-term cardiovascular outcome trials of the combination remain limited.
Evidence: Schwalfenberg 2017 review (J Nutr Metab) summarises the mechanistic case and the available trials. Maresz 2015 (Integr Med) gives the cardiovascular-calcification rationale. Most published trials have studied each vitamin alone; the combined stack is supported by mechanism + observational data more than by direct combination RCTs. [10,11]
Doses studied: 1000–2000 IU D3 with 90–180 µg K2 (MK-7 form preferred for half-life)
Magnesium
Moderate evidenceD3 needs magnesium as a cofactor — without enough, supplementation is less effective.
Each step of vitamin D metabolism — from cholecalciferol synthesis in the skin, to 25-hydroxylation in the liver, to 1-alpha-hydroxylation in the kidney, to binding by vitamin D-binding protein, to receptor activation — uses magnesium-dependent enzymes (CYP27A1, CYP27B1, CYP24A1) or ATP-magnesium complexes. Population studies report that adults with low magnesium intake show blunted serum 25-OH-D response to D3 supplementation. The relationship is co-factor dependence, not synergy in the classical sense — adequate magnesium does not enhance D3 beyond normal function; insufficient magnesium impairs it.
Evidence: Uwitonze & Razzaque 2018 (J Am Osteopath Assoc) reviews the cofactor relationship and the magnesium dependence of vitamin D activation. Observational data is consistent; intervention trials testing magnesium repletion as a route to higher 25-OH-D are limited. [12,13]
Doses studied: Co-occurring adequacy: 10 µg (400 IU) D3 with 300–375 mg magnesium daily (UK RNI)
Calcium (Ca)
Strong evidenceThe canonical bone-health pairing — vitamin D3 enables intestinal calcium absorption; the UK Article 14 disease-risk-reduction claim for postmenopausal bone loss applies to the combination.
Active intestinal calcium absorption depends on calcitriol (1,25-dihydroxyvitamin D), which upregulates the apical calcium channel TRPV6 and the intracellular calcium-binding protein calbindin-D9k in enterocytes. Without adequate vitamin D status, a substantial proportion of dietary or supplemental calcium is not absorbed. The UK Article 14 disease-risk-reduction claim "Calcium and vitamin D help reduce the loss of bone mineral in post-menopausal women. Low bone mineral density is a risk factor for osteoporotic bone fractures" applies to combined intake at ≥1200 mg calcium + ≥20 µg vitamin D from all sources. UK NHS recommends 10 µg/day vitamin D for all adults autumn/winter.
Evidence: UK Article 14 disease-risk-reduction claim authorised. Multiple Cochrane and meta-analytic reviews confirm bone-density and fracture-risk benefits in post-menopausal supplementation when both nutrients are adequate. [6,6]
Doses studied: 1000 mg/day elemental calcium plus 800 IU (20 µg) vitamin D3 in the post-menopausal bone-health pathway; lower-dose maintenance (10 µg D3) sufficient for autumn/winter adequacy in most adults
Zinc
Strong evidenceImmune-cluster trio with vitamin C — three different UK Article 13.1 immune-claim mechanisms stacked.
Vitamin D3 induces antimicrobial peptide expression (cathelicidin LL-37, defensins) in monocytes and respiratory epithelium and modulates Th1/Th17 responses. Zinc supports immune-cell function separately and has direct anti-rhinoviral activity (zinc binding to rhinovirus 3C-protease). Vitamin C supports neutrophil chemotaxis + lymphocyte proliferation. Three separate mechanisms, three separate UK Article 13.1 immune claims — classical winter-immune formulation.
Evidence: All three nutrients carry UK Article 13.1 authorised claim "contributes to the normal function of the immune system." Vitamin D + winter respiratory infection: Martineau 2017 IPD meta-analysis (BMJ) supportive in deficient subgroups. [6,6]
Doses studied: 10–25 mg zinc + 10–25 µg vitamin D3 + 80–1000 mg vitamin C daily
Vitamin A (retinol and provitamin-A carotenoids)
Moderate evidenceFat-soluble vitamin cluster — A + D + E + K all fat-soluble; commonly co-formulated.
Vitamins A, D, E, and K share fat-soluble pharmacokinetics — absorbed via the intestinal lipid-uptake pathway, transported in chylomicrons + lipoproteins, stored in liver and adipose tissue. Different cellular mechanisms: vitamin A retinoid-receptor signalling (RAR/RXR); vitamin D VDR/RXR signalling. Fish liver oils naturally co-deliver A and D — pregnancy precaution applies to high-retinol cod liver oil at >700 µg/day combined preformed vitamin A intake.
Evidence: UK Article 13.1 claims authorised for vitamin A (immune function, iron metabolism, normal vision) and vitamin D (immune function, bone, muscle, calcium homeostasis). Co-formulation common; not directly trialled as a stack. [6,6]
Doses studied: 800 µg vitamin A with 10–25 µg vitamin D3 daily
Fish Oil (Long-Chain Omega-3 EPA / DHA, Marine Source)
Moderate evidenceCardiovascular + immune cluster — fish oil EPA/DHA + vitamin D3 both feature in cardiovascular and immune authorised-claim contexts.
Fish oil EPA/DHA: heart, brain, vision UK Article 13.1 claims. Vitamin D3: immune, bone, muscle, calcium homeostasis. Mechanism complementary across two distinct nutrient axes. Cod liver oil naturally co-delivers vitamin D3 and EPA/DHA + preformed vitamin A — pregnancy precaution applies because of A content.
Evidence: UK Article 13.1 claims authorised for fish oil (250 mg EPA+DHA heart claim) and vitamin D3 (multiple claims). VITAL trial (Manson 2019) tested both at moderate doses without clear cardiovascular benefit in non-deficient adults. [6]
Doses studied: 1000–2000 mg fish oil with 10–25 µg vitamin D3 daily
Vegan Omega-3 (Algal EPA + DHA)
Moderate evidenceVegan-friendly cluster — algal/lichen-source D3 + algal-source omega-3 bypass fish liver oil traditional source.
Cholecalciferol (vitamin D3) from lichen + DHA/EPA from microalgae provide vegan-friendly access to two nutrients historically sourced from fish. Mechanism per the fish-oil pairing, with the same UK Article 13.1 claim coverage.
Evidence: UK Article 13.1 claims authorised. Lichen-source D3 is bioequivalent to fish-liver D3 in serum 25-OH-D response trials. [6]
Doses studied: 500–1000 mg algal oil with 10–25 µg lichen-source vitamin D3 daily
Creatine
Moderate evidenceActive-living cluster — creatine ATP buffering + vitamin D3 muscle function (UK Article 13.1).
Creatine phosphate is the body''s short-term ATP-buffer system. Vitamin D supports muscle function — UK Article 13.1 "Vitamin D contributes to the maintenance of normal muscle function." The pairing addresses two complementary axes of muscular performance and recovery; commonly stacked in evidence-led active-adult formulations.
Evidence: UK Article 13.1 claims authorised for both: creatine (3 g/day performance claim); vitamin D (muscle function claim). Combination not directly trialled. [6,6]
Doses studied: 3 g/day creatine monohydrate with 10–25 µg vitamin D3 daily
Elderberry (Sambucus nigra, Black Elder)
Limited evidenceWinter-immune-cluster pairing — vitamin D3 (UK NHS-recommended at 10 µg/day) plus elderberry adjunct for cold-symptom support.
Vitamin D is required for normal immune-cell function and carries the UK Article 13.1 authorised claim. UK NHS recommends 10 µg/day for everyone autumn/winter when sunlight UVB synthesis is insufficient. Elderberry (Sambucus nigra) provides anthocyanin content with traditional cold/flu adjunct framing; no UK authorised claim. Vitamin D supplies the lawful immune claim while elderberry contributes the traditional-use narrative.
Evidence: UK Article 13.1 vitamin D immune-function claim authorised. Vitamin D + winter respiratory infection prevention: Martineau 2017 IPD meta-analysis supportive in deficient subgroups. Elderberry cold-symptom evidence modest (Tiralongo 2016). Combination not directly trialled. [6]
Doses studied: 10–25 µg/day vitamin D3 + elderberry extract 300–1000 mg, daily through autumn/winter
Inositol (Myo-Inositol, D-Chiro-Inositol)
Limited evidencePCOS / preconception cluster — both PCOS and pregnancy contexts feature vitamin D3 supplementation alongside inositol.
Vitamin D insufficiency is more common in PCOS women than in age-matched non-PCOS women in cohort studies; mechanism debated (insulin resistance + adiposity links). UK NHS pregnancy guidance recommends 10 µg/day vitamin D3 throughout pregnancy and breastfeeding. Inositol (myo + d-chiro forms in 40:1 ratio) addresses PCOS insulin signalling separately. Different mechanisms; both feature in PCOS / preconception protocols.
Evidence: UK NHS pregnancy vitamin D recommendation (10 µg/day) is universal. Inositol PCOS evidence is from Cochrane Showell 2018. Combination not directly trialled in PCOS RCTs. [6]
Doses studied: Myo-inositol 2–4 g/day with vitamin D3 10–25 µg/day. Higher D3 doses only in documented insufficiency under pharmacist/GP supervision.
Retinol (Vitamin A1, all-trans-retinol)
Limited evidenceNuclear-receptor signalling overlap in keratinocyte differentiation — retinoic acid (RAR/RXR) and calcitriol (VDR/RXR) share the RXR partner; topical psoriasis pathway uses analogues of both.
Retinoid receptors (RAR-α/β/γ) and the vitamin D receptor (VDR) both heterodimerise with retinoid X receptors (RXR-α/β/γ) to form transcriptionally active receptor complexes. The shared RXR partner means both pathways converge on keratinocyte differentiation and skin-barrier programmes. UK MHRA/NICE psoriasis pathways use prescription topical calcipotriol (vitamin D analogue) plus topical retinoid combinations.
Evidence: Receptor-signalling biochemistry well established. UK NICE CKS psoriasis pathway recommends topical calcipotriol +/- topical retinoid combinations. Cosmetic-tier oral D3 + topical retinol pairing not directly trialled but mechanistically coherent. [6]
Doses studied: Topical retinol 0.2–0.5% (evening) + oral vitamin D3 10 µg/day (UK NHS recommendation). For psoriasis, consult GP — prescription pathway differs.
Berberine
Limited evidenceMetabolic cluster — berberine insulin-sensitisation alongside vitamin D3's metabolic-syndrome adjunct context.
Berberine activates AMP-activated protein kinase (AMPK) in hepatocytes and skeletal muscle, modestly improving insulin sensitivity and lipid profile in T2D meta-analyses. Vitamin D insufficiency is associated with metabolic-syndrome features in cohort studies; mechanism debated. Different mechanisms; both surface in metabolic-syndrome supplement stacks.
Evidence: Berberine T2D meta-analyses (Lan 2015) support modest HbA1c reduction. UK Article 13.1 vitamin D claims authorised. Combination not directly trialled. [6]
Doses studied: 500–1500 mg berberine with 10–25 µg vitamin D3 daily
Akkermansia muciniphila (next-generation probiotic)
Limited evidenceMetabolic-syndrome adjacency — vitamin D3 immune/bone claims + Akkermansia gut-barrier and insulin-sensitivity emerging evidence.
Vitamin D3 supports immune-cell function + calcium homeostasis + cardiovascular health (UK Article 13.1 immune + bone + muscle + calcium claims). Akkermansia muciniphila is a next-generation probiotic with mucin-layer-thickening + insulin-sensitivity emerging evidence (EU Novel Food 2021/1577 authorisation for pasteurised form). Different mechanisms; both feature in metabolic-health supplement stacks.
Evidence: UK Article 13.1 vitamin D claims authorised. Akkermansia pasteurised-form evidence: Depommier 2019 (Nat Med) human pilot. Combination not directly trialled. [6]
Doses studied: Vitamin D3 10–25 µg/day + pasteurised Akkermansia 10⁹–10¹⁰ CFU/day